ArticlePLoS pathogens2016
Fcγ-receptor IIa-mediated Src Signaling Pathway Is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection.
Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 34 citations in OpenAlex.
- A novel FcγRIIa-TRIM54-STAT2 axis negatively regulates type I interferon signaling and promotes viral susceptibility in human monocytes.Journal of virology · 2026Article
- Griffithsin-mediated inhibition of cellular entry of hemorrhagic fever viruses and insights into its mechanisms.Journal of virology · 2026Article
- Functional Antibody-Dependent Enhancement as an Immune Assessment Platform: Development, Standardization, and Translational Interpretation in Flavivirus Research.Pathogens (Basel, Switzerland) · 2026Review
- FcγRIIA signalling as a host-associated determinant of endosomal trafficking and antibody-dependent enhancement in flavivirus infection.Frontiers in immunology · 2026Article
- Fast-acting single-dose vesicular stomatitis virus-Sudan virus vaccine: a challenge study in macaques.The Lancet. Microbe · 2025Article
- Antibody-dependent enhancement of ORFV uptake into host cells.Virulence · 2025Article
- Dasatinib inhibits betacoronavirus replication in macrophages and attenuates pro-inflammatory mediators via SRC-MAPK pathway modulation.Medical microbiology and immunology · 2025Article
- Single-dose VSV-Sudan virus vaccine protects from lethal Sudan virus infection within one week: a challenge study in macaques: VSV-SUDV but not VSV-EBOV protects NHPs from Sudan virus disease.bioRxiv : the preprint server for biology · 2025Article
- Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever.International journal of molecular sciences · 2025Review
- Visualizing the Internalization of Marburg Viruslike Particles into Living Cells.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Molecular insights into the Ebola virus life cycle.Nature microbiology · 2024Review
- Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.Microbiology spectrum · 2022Article
- Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective.Journal of the Indian Institute of Science · 2022Review
- Development of an imaging system for visualization of Ebola virus glycoprotein throughout the viral lifecycle.Frontiers in microbiology · 2022Article
- Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses.Microorganisms · 2021Review
- Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome.Haematologica · 2021Review
- The Ebola virus soluble glycoprotein contributes to viral pathogenesis by activating the MAP kinase signaling pathway.PLoS pathogens · 2021Article
- Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates.PLoS neglected tropical diseases · 2021Article
- Covid-19 and dengue: Double punches for dengue-endemic countries in Asia.Reviews in medical virology · 2021Review
- An Ebola,Computational and structural biotechnology journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 3 countries.
Funding
Abstract
Antibody-dependent enhancement (ADE) of Ebola virus (EBOV) infection has been demonstrated in vitro, raising concerns about the detrimental potential of some anti-EBOV antibodies. ADE has been described for many viruses and mostly depends on the cross-linking of virus-antibody complexes to cell surface Fc receptors, leading to enhanced infection. However, little is known about the molecular mechanisms underlying this phenomenon. Here we show that Fcγ-receptor IIa (FcγRIIa)-mediated intracellular signaling through Src family protein tyrosine kinases (PTKs) is required for ADE of EBOV infection. We found that deletion of the FcγRIIa cytoplasmic tail abolished EBOV ADE due to decreased virus uptake into cellular endosomes. Furthermore, EBOV ADE, but not non-ADE infection, was significantly reduced by inhibition of the Src family protein PTK pathway, which was also found to be important to promote phagocytosis/macropinocytosis for viral uptake into endosomes. We further confirmed a significant increase of the Src phosphorylation mediated by ADE. These data suggest that antibody-EBOV complexes bound to the cell surface FcγRIIa activate the Src signaling pathway that leads to enhanced viral entry into cells, providing a novel perspective for the general understanding of ADE of virus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.